Testing bevacizumab with chemo and immunotherapy for small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies whether adding bevacizumab to chemo plus immunotherapy (including atezolizumab) can improve outcomes in extensive-stage small cell lung cancer (ES-SCLC) that has spread to the liver. It may help by blocking tumor blood vessel growth while boosting anti-cancer immune and treatment effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed extensive-stage small cell lung cancer (ES-SCLC) and liver metastases seen on scans
- You have not had any prior treatment for ES-SCLC (chemo/immunotherapy-naïve)
- Your cancer has at least one measurable spot on scans that can be followed over time
- If you have brain metastases, they must be limited to certain areas and must be stable after any treatment
- Your overall health and blood counts must be strong enough for treatment (based on recent lab tests)
- Your blood pressure, urine protein level, bleeding/clot history, and medications must meet safety rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination treatment for extensive-stage small cell lung cancer: intensive chemotherapy plus an immunotherapy drug (adebrelimab), followed by a stem cell transplant using your own cells. The goal is to see if this powerful approach can shrink tumors and help you live longer.
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
This trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps people with extensive-stage small cell lung cancer. It is for those who have not had treatment for this stage yet.
This study tests a new combination therapy for extensive-stage small cell lung cancer (cancer that has spread beyond the lung). The treatment includes an immunotherapy drug, a drug that blocks blood vessel growth to tumors, and chemotherapy. It aims to see how well this combination works in people who have not yet been treated for this cancer.
This trial tests a combination of an immunotherapy drug (adebrelimab), chemotherapy, and radiation therapy as a first treatment for extensive-stage small cell lung cancer. The goal is to see if this combination helps people live longer and feel better.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.